Medical expertise company RubiconMD on Thursday announced a suite of COVID-19 vaccine eConsults and resources to continue to support the primary care physicians deliver the clear, accurate communication vital in the fight against the pandemic.
RubiconMD's panel of COVID-19 vaccine experts will review the real eConsult case studies and leverage educational resources curated in partnership with CONVINCE USA Initiative at the CUNY Graduate School of Public Health and Health Policy.
Based on the survey of RubiconMD clinicians, about 50% of respondents felt that they do not have all the resources needed to make vaccine decisions to adequately address patient questions. Respondents strongly emphasized the need for digestible summaries of vaccine recommendations, clinical guidelines for patients with complex conditions, and multilingual patient-facing resources.
Following the feedback, RubiconMD encourages clinicians to reach out to their specialist experts with any vaccine questions and leverage the dashboard for continually updated curated content and CME eligible webinars.
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
GC Biopharma granted CMO rights for Curevo Vaccine's shingles vaccine